Workshop focused on strengthening sterile processing standards, infection prevention, and CSSD best practices in healthcare settings
The move puts a spotlight on one of psychiatry’s most persistent clinical challenges: misdiagnosis and delay
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
Collaboration to accelerate mRNA neoantigen therapy development for colorectal and pancreatic cancers using advanced immunology and dark genome insights
Former Novo Nordisk and Pharmanovia executive to lead next growth phase in NAD diagnostics and personalised health innovation
The company receives approval for blood-based test enabling objective differentiation of schizophrenia and bipolar disorder
With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
Q2 2026 analysis shows expanding approvals, stronger uptake, and a shift toward evidence-driven biosimilar evaluation
The collaboration underscores a broader industry shift toward hybrid research models that integrate computational biology with advanced experimental systems
Subscribe To Our Newsletter & Stay Updated
